Dr. Reddy’s Laboratories (RDY) Projected to Release Quarterly Earnings on Friday

Dr. Reddy’s Laboratories (NYSE:RDY) is projected to post its Q2 26/27 results before the market opens on Friday, October 23rd. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.0951 per share and revenue of $892.16 million for the quarter. Interested persons can check the company’s upcoming Q2 26/27 earnings overview page for the latest details on the call scheduled for Friday, October 23, 2026 at 10:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Thursday, July 23rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $850.26 million during the quarter, compared to analyst estimates of $850.56 million. Dr. Reddy’s Laboratories had a net margin of 10.15% and a return on equity of 9.49%. On average, analysts expect Dr. Reddy’s Laboratories to post $0.45 EPS for the current fiscal year and $0.57 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY opened at $13.27 on Wednesday. Dr. Reddy’s Laboratories has a 1 year low of $11.36 and a 1 year high of $15.67. The stock has a market capitalization of $11.07 billion, a PE ratio of 30.15, a PEG ratio of 2.73 and a beta of 0.29. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.39 and a current ratio of 1.90. The stock has a 50-day simple moving average of $12.30 and a 200-day simple moving average of $12.91.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RDY. BNP Paribas Exane raised shares of Dr. Reddy’s Laboratories to an “outperform” rating and set a $14.80 price objective on the stock in a research report on Monday, October 12th. Weiss Ratings cut Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Wall Street Zen raised Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Citigroup raised Dr. Reddy’s Laboratories from a “sell” rating to a “buy” rating and upped their price objective for the stock from $1,040.00 to $1,450.00 in a research report on Tuesday, September 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dr. Reddy’s Laboratories has an average rating of “Hold” and an average price target of $732.40.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible.

Its business includes generic prescription drugs, active pharmaceutical ingredients, biosimilars, specialty products and over-the-counter consumer healthcare products. Dr. Reddy’s offers medicines across therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology.

The company serves patients and healthcare providers in India, the United States, Europe and a range of other international markets, including emerging markets.